873436-91-0

Basic information

• Product Name: 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine
• Synonyms: 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine;PU-H 71;8-((6-iodobenzo[d][1,3]dioxol-5-yl)thio)-9-(3-(isopropylaMino)propyl)-9H-purin-6-aMine;PU-H71 Trifluoroacetic Acid;9H-Purine-9-propanamine, 6-amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-;NSC 750424;6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine PU-H71 Trifluoroacetic Acid;PU-H71, >=98%
• CAS NO: 873436-91-0
• Molecular Formula: C18H21IN6O2S
• Molecular Weight: 512.36781
• Product Categories: API;Inhibitors
• Mol File: 873436-91-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 650.6±65.0 °C(Predicted)
• Appearance: /
• Density: 1.84
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 10.16±0.29(Predicted)
• CAS DataBase Reference: 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine(873436-91-0)
• EPA Substance Registry System: 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine(873436-91-0)

Safety Data

• Hazardous Substances Data: 873436-91-0(Hazardous Substances Data)

Usage

Description

6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine, also known as PU-H71, is a potent Hsp90 inhibitor with an IC50 of 50 nM. Hsp90 is a protein that plays a critical role in modulating the activity of many cell signaling proteins, making it an attractive target for anti-cancer therapeutics. PU-H71 has been studied for its potential as an anti-Parkinson's disease agent.

Uses

Used in Pharmaceutical Industry:
PU-H71 is used as a potent Hsp90 inhibitor for its potential anti-cancer therapeutic applications. By inhibiting Hsp90, it can modulate the activity of various cell signaling proteins, leading to the disruption of cancer cell growth and survival.
Used in Neurodegenerative Disease Research:
PU-H71 is used as a potential anti-Parkinson's disease agent. Studies have indicated that Hsp90 inhibitors like PU-H71 may have therapeutic potential in treating neurodegenerative diseases such as Parkinson's by modulating the activity of proteins involved in the disease progression.

Upstream product

• 873437-14-0 {3-[6-amino-8-(6-iodo-benzo[1,3]dioxol-5-ylsulfanyl)-purin-9-yl]-propyl}-isopropyl-carbamic acid tert-butyl ester 
• 873437-13-9 tert-butyl N-(3-hydroxypropyl)-N-(isopropyl)carbamate 
• 905449-67-4 3-(tert-butoxycarbonyl-isopropylamino)propyl tosylate 
• 873436-88-5 8-(benzo[1,3]dioxol-5-ylsulfanyl)adenine 
• 873436-89-6 8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-6-amine 
• 33918-15-9 3-(isopropylamino)-1-propan-ol 
• 14268-66-7 benzo[1,3]dioxolo-5-ylamine 
• 5876-51-7 5-iodo-1,3-benzodioxole 
• 7390-62-7 8-mercaptoadenine 
• 1240419-78-6 9-(3-bromopropyl)-8-((6-iodobenzo[d][1,3]dioxol-5-yl)thio)-9H-purin-6-amine 
• 75-31-0 isopropylamine 

Relevant articles and documents

A facile and efficient synthesis of d6-labeled PU-H71, a purine-scaffold Hsp90 inhibitor

PU-H71 is a purine-scaffold Hsp90 inhibitor currently undergoing late stage preclinical evaluation for the treatment of cancer. In this investigation, we present a simple method for the synthesis of d6-labeled PU-H71 for use as an internal standard to accurately quantitate the drug in biological matrices based on an LC-MS-MS method. PU-H71-d6 was synthesized in five steps using readily available 1,3-dibromopropane-d6 and is an important compound for the advancement of our clinical program. Copyright